NEW YORK (GenomeWeb) — Qiagen last week announced its plans to fill one of the few remaining gaps in its molecular diagnostic product portfolio — multiplex molecular infectious disease, or 'syndromic' testing — through the acquisition of Spanish molecular diagnostics developer Stat-Dx for up to $191 million.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.